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Abstract
Background: A mixed-effects model repeated measures approach (MMRM) was specified as the primary analysis
in the Phase III clinical trials of duloxetine for the treatment of major depressive disorder (MDD). Analysis of
covariance using the last observation carried forward approach to impute missing values (LOCF_ANCOVA) was
specified as a secondary analysis. Previous research has shown that MMRM and LOCF_ANCOVA yield identical
endpoint results when no data are missing, while MMRM is more robust to biases from missing data and thereby
provides superior control of Type I and Type II error compared with LOCF_ANCOVA. We compared results
from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how
the choice of primary analysis may influence interpretations of efficacy.
Methods: Results were obtained from the eight acute-phase clinical trials that formed the basis of duloxetine's
New Drug Application for the treatment of MDD. All 202 mean change analyses from the 20 rating scale total
scores and subscales specified a priori in the various protocols were included in the comparisons.
Results: In 166/202 comparisons (82.2%), MMRM and LOCF_ANCOVA agreed with regard to the statistical
significance of the differences between duloxetine and placebo. In 25/202 cases (12.4%), MMRM yielded a
significant difference when LOCF_ANCOVA did not, while in 11/202 cases (5.4%), LOCF_ANCOVA produced
a significant difference when MMRM did not. In 110/202 comparisons (54.4%) the p-value from MMRM was lower
than that from LOCF_ANCOVA, while in 69/202 comparisons (34.2%), the p-value from LOCF_ANCOVA was
lower than that from MMRM. In the remaining 23 comparisons (11.4%), the p-values from LOCF_ANCOVA and
MMRM were equal when rounded to the 3rd decimal place (usually as a result of both p-values being < .001). For
the HAMD17 total score, the primary outcome in all studies, MMRM yielded 9/12 (75%) significant contrasts,
compared with 6/12 (50%) for LOCF_ANCOVA. The expected success rate was 80%.
Conclusions: Important differences exist between MMRM and LOCF_ANCOVA. Empirical research has clearly
demonstrated the theoretical advantages of MMRM over LOCF_ANCOVA. However, interpretations regarding
the efficacy of duloxetine in MDD were unaffected by the choice of analytical technique.
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Background
Treatment effects are often evaluated by comparing
change over time in outcome measures. However, valid
analyses of longitudinal data can be problematic, particu-
larly if some data are missing for reasons related to the
outcome measure [1,2]. Since the problem of missing
data is almost ever-present in clinical trials, numerous
methods for handling missingness have been proposed,
examined, and implemented [3].
A common method of analyzing clinical trial data is to use
analysis of variance or analysis of covariance (ANOVA or
ANCOVA) with missing data imputed by the last observa-
tion carried forward approach (LOCF_ANCOVA). The
popularity of LOCF_ANCOVA may be due to its simplic-
ity, and also the belief that violations of the restrictive
assumptions inherent to LOCF_ANCOVA lead to a con-
servative analysis [4]. Considerable advances in statistical
methodology, and in our ability to implement these
methods, have been made in recent years. Thus, methods
that require less restrictive assumptions than
LOCF_ANCOVA are now readily implemented. For exam-
ple, likelihood-based repeated measures approaches have
a number of theoretical and practical advantages for anal-
ysis of longitudinal data with dropout [4].
One such method, termed MMRM (Mixed Model
Repeated Measures [5]), has been studied extensively in
the context of neuropsychiatric clinical trials [6-9]. In
these studies, MMRM was found to be more robust to
biases from missing data than LOCF_ANCOVA, and
thereby provided superior control of Type I and Type II
errors. The LOCF_ANCOVA method was shown to under-
estimate treatment group differences in some scenarios,
while overestimating differences in others. When no data
were missing, the two methods yielded identical results.
The MMRM approach was specified as the primary analy-
sis in the Phase III clinical trials of duloxetine for the treat-
ment of major depressive disorder (MDD), while
LOCF_ANCOVA was specified as a secondary analysis. In
the present investigation, we provide a comprehensive
summary of results from MMRM and LOCF_ANCOVA in
the eight acute-phase clinical trials that formed the basis
for duloxetine's New Drug Application (NDA) for MDD.
The primary objective of this investigation was to deter-
mine whether differences in results between MMRM and
LOCF_ANCOVA influenced conclusions regarding the
efficacy of duloxetine.
Methods
Data
The data source for this investigation was the eight acute-
phase clinical trials in which duloxetine was compared
with placebo in the treatment of MDD. Relevant details of
these studies are highlighted in Table 1.
Results are summarized from all rating scale total scores,
subscales, and global assessments that were specified a pri-
ori  in the various protocols to be analyzed for mean
change from baseline to endpoint, and were collected at
more than one postbaseline time point (Table 2). Efficacy
measures that were assessed only at baseline and endpoint
were not included in this summary because repeated
measures analyses were not possible for these outcomes.
Thus, the present investigation included every rating scale
total score and subscale from every clinical trial relevant to
duloxetine's NDA for an indication in major depression.
In total, 20 efficacy and health outcome variables were
included in the summary of MMRM and LOCF_ANCOVA.
Some of the eight trials included multiple dose arms;
therefore, some outcomes were assessed in as many as 12
comparisons with placebo.
Comparisons of MMRM and LOCF_ANCOVA focused on
contrasts between duloxetine and placebo. However, six
of the studies also included known effective antidepres-
sants approved for marketing in the United States and
other countries. Contrasts between duloxetine and the
active comparators are not included in this summary since
these results may draw attention to the drug versus drug
results and detract from the primary focus of comparing
MMRM with LOCF_ANCOVA.
Statistical analysis
This summary makes no attempt to provide formal statis-
tical comparisons of results from MMRM and
LOCF_ANCOVA. Previous research has demonstrated
conclusively that in the absence of missing data the two
methods yield identical endpoint contrasts, while differ-
ences do exist in the presence of subject dropout [6-9].
Furthermore, formal statistical comparisons are typically
applied to random samples obtained from larger popula-
tions in order to assess the uncertainty associated with the
sampling. However, the eight studies included in this
summary are not a sample, but rather represent all of the
acute-phase, double-blind, placebo-controlled trials of
duloxetine. Thus, there is no uncertainty associated with
sampling. Consequently, results from the two methods
need only be summarized in order to assess how
differences between the methods may influence overall
conclusions regarding the efficacy of duloxetine.
Three overall summary measures were used to compare
results from the two analytic techniques: 1) With regard to
statistical significance of the difference between duloxet-
ine and placebo, the proportion of outcomes showing
agreement between MMRM and LOCF_ANCOVA was
compared with the proportion of outcomes for whichBMC Psychiatry 2004, 4:26 http://www.biomedcentral.com/1471-244X/4/26
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Table 1: Summary of studies included in the comparisons between MMRM and LOCF_ANCOVA
Study Treatment Duration Drug Number of Patients Drug Dose & Design
1 9 weeks Placebo 122 -
Duloxetine 123 60 mg/d (QD)
2 9 weeks Placebo 139 -
Duloxetine 128 60 mg/d (QD)
3 8 weeks Placebo 70 -
Duloxetine 70 40–120 mg/d (20 mg-60 mg BID)
Fluoxetine 33 20 mg/d (QD)
4 8 weeks Placebo 75 -
Duloxetine 82 40–120 mg/d (20 mg-60 mg BID)
Fluoxetine 37 20 mg/d (QD)
5 8 weeks Placebo 90 -
Duloxetine 91 40 mg/d (20 mg BID)
Duloxetine 84 80 mg/d (40 mg BID)
Paroxetine 89 20 mg/d (QD)
6 8 weeks Placebo 89 -
Duloxetine 86 40 mg/d (20 mg BID)
Duloxetine 91 80 mg/d (40 mg BID)
Paroxetine 87 20 mg/d (QD)
7 8 weeks Placebo 93 -
Duloxetine 95 80 mg/d (40 mg BID)
Duloxetine 93 120 mg/d (60 mg BID)
Paroxetine 86 20 mg/d (QD)
8 8 weeks Placebo 99 -
Duloxetine 93 80 mg/d (40 mg BID)
Duloxetine 103 120 mg/d (60 mg BID)
Paroxetine 97 20 mg/d (QD)
Table 2: Outcomes included in the summary of results.
17-item Hamilton Rating Scale for Depression (HAMD17)
Total score [24]
Core subscale (items 1, 2, 3, 7, 8) (not published)
Maier subscale (items 1, 2, 7, 8, 9, 10) [25]
Anxiety/Somatization subscale (items 10, 11, 12, 13, 15, 17) [26]
Retardation subscale (items 1, 7, 8, 14) [27]
Sleep subscale (items 4, 5, 6) [27]
Montgomery-Asberg Depression Rating scale [28]
Hamilton Anxiety Rating Scale total score [29]
Clinical Global Impression of Severity [26]
Patient Global Impression of Improvement [26]
Visual Analog Scale for pain [30]
Overall pain severity
Headaches
Back pain
Shoulder pain
Time in pain while awake
Interference with daily activities
Somatic Symptom Inventory [31]
26 Item total score
28 Item total score (includes 2 additional questions on painful physical symptoms)
Quality of Life in Depression Scale total score [32]BMC Psychiatry 2004, 4:26 http://www.biomedcentral.com/1471-244X/4/26
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MMRM and LOCF_ANCOVA yielded disparate results; 2)
The proportion of outcomes for which MMRM yielded the
lowest p-value was compared with the corresponding pro-
portion for LOCF_ANCOVA; 3) The number of outcomes
for which "substantial evidence of efficacy" was demon-
strated. In regulatory settings, the criterion for substantial
evidence of efficacy is frequently the demonstration of a
statistically significant advantage over placebo in two or
more studies. This criterion was utilized here to define
substantial evidence of efficacy for a particular outcome.
The frequency of lower p-values provides a "fine-tuned"
measure of sensitivity of the two analytic methods. How-
ever, in certain cases such an assessment may actually be
misleading. For example, to distinguish between p= .800
and p = .810, or between p =. 002 and p =. 003, implies
that the methods yielded different results when in fact the
similarities far outweigh the differences. Hence, it is
equally appropriate to simply categorize based upon the
presence or absence of a significant difference. Further-
more, given the large number of outcomes assessed across
the eight studies, it would not be surprising to see the two
methods disagree with regard to statistical significance on
at least a small number of outcomes. Therefore, perhaps
the most clinically meaningful summary measure is the
number of outcomes for which substantial evidence of
efficacy was demonstrated.
Three outcomes were selected for more detailed presenta-
tion of results: the 17-item Hamilton Rating Scale for
Depression (HAMD17) total score, the HAMD17 Maier
subscale, and the Visual Analog Scale (VAS) for overall
pain severity. The HAMD17 total score was an obvious
choice as it was the primary outcome in all studies. The
other outcomes were selected since they are frequently
focal points in manuscripts and presentations regarding
duloxetine's efficacy. Finally, we provide case studies to
help explain how and why results from MMRM and
LOCF_ANCOVA may differ.
MMRM and LOCF_ANCOVA analyses were specified in
the Phase III duloxetine protocols as follows. In
LOCF_ANCOVA analyses, change from baseline to the
last observation was the dependent variable. Treatment
and investigative site were included as categorical inde-
pendent variables, and baseline severity was included as a
covariate. In MMRM analyses, change from baseline to all
postbaseline times was the dependent variable. Independ-
ent variables included the fixed, categorical effects of
investigative site, treatment, time, and the treatment-by-
time interaction, along with the continuous covariates of
baseline severity and the baseline severity by time interac-
tion. Parameters were estimated using Restricted Maxi-
mum Likelihood with the Newton-Raphson algorithm.
The protocols specified an algorithm for choosing the best
fitting covariance structure. In all cases an unstructured
matrix provided the best fit. Hence, within-patient errors
were modeled using an unstructured covariance matrix.
Results
The protocols for the eight studies in the duloxetine NDA
specified a priori a total of 202 mean change analyses for
the 20 rating scale total scores or subscales. The frequency
of significant outcomes and the frequency of higher/lower
p-values for each analytic technique are summarized in
Table 3. MMRM and LOCF_ANCOVA agreed with regard
to substantial evidence of efficacy for 18 of the 20 out-
comes, with each analysis yielding substantial evidence
for 15 outcomes. That is, MMRM and LOCF_ANCOVA
both found substantial evidence of efficacy for 14 out-
comes; both methods did not find substantial evidence
for four outcomes; and each method found substantial
evidence when the other did not for one outcome (Table
3).
In 166/202 outcomes (82.2%), MMRM and
LOCF_ANCOVA agreed with regard to the statistical sig-
nificance of the difference between duloxetine and pla-
cebo. In 25 cases (12.4%) MMRM yielded a significant
difference whereas LOCF_ANCOVA did not, while in 11
cases (5.4%) LOCF_ANCOVA yielded a significant differ-
ence when MMRM did not.
Both methods tended to yield significance more fre-
quently in depression rating scales and subscales than in
outcomes related to somatic and painful physical symp-
toms. The studies were generally underpowered for these
secondary somatic and pain outcomes owing to the
greater variance in changes score for these outcomes. For
example, the variance in VAS overall pain severity was
approximately nine-fold greater than the variance in
HAMD17 total scores, leading to a three-fold greater stand-
ard error.
In 110 of the 202 outcomes (54.4%) the p-value from
MMRM was lower than that from LOCF_ANCOVA, while
in 69 cases (34.2%) the p-value from LOCF_ANCOVA
was lower than that from MMRM. In the remaining 23
cases (11.4%) the p-values from LOCF_ANCOVA and
MMRM were equal when rounded to the 3rd decimal place
(usually as a result of both p-values being < .001).
More detailed results from the three focus outcomes
(HAMD17 total score, HAMD17 Maier subscale, and VAS
overall pain) are presented in Table 4. In the case of the
HAMD17 total score, the advantage of duloxetine over pla-
cebo in mean change from baseline to endpoint from
MMRM analyses was greater than the corresponding
advantage from LOCF_ANCOVA in 9/12 comparisons
(Table 4). In 9/12 comparisons the p-value from MMRMBMC Psychiatry 2004, 4:26 http://www.biomedcentral.com/1471-244X/4/26
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was lower than that from LOCF_ANCOVA, while
LOCF_ANCOVA yielded a smaller p-value in one case, and
p-values were identical in the two remaining cases. In 3/12
comparisons, MMRM yielded a significant difference when
LOCF_ANCOVA did not, but in no instance did
LOCF_ANCOVA produce a significant difference when
MMRM did not. When averaging results across all eight stud-
ies, the advantage of duloxetine over placebo in HAMD17
Table 3: Summary of results from MMRM and LOCF_ANCOVA in duloxetine clinical trials.
Outcome Frequency of 
significant 
outcomes1MMRM 
LOCF_ANCOVA
P-value lower with 
MMRM 
LOCF_ANCOVA
Outcome significant 
with MMRM but not 
LOCF_ANCOVA
Outcome significant 
with LOCF_ANCOVA 
but not MMRM
HAMD17
Total score 9\12 6\12 9\12 1\12 3\12 0\12
Core subscale 9\12 8\12 5\12 3\12 2\12 1\12
Maier subscale 10\12 9\12 6\12 2\12 2\12 1\12
Anxiety subscale 6\12 5\12 7\12 3\12 2\12 1\12
Retardation subscale 8\12 6\12 6\12 3\12 4\12 2\12
Sleep subscale 1\12 1\12 10\12 2\12 0\12 0\12
MADRS Total score 5\10 3\10 7\10 2\10 2\10 0\10
HAMA Total score 3\10 3\10 4\10 5\10 0\10 0\10
CGI-Severity 6\12 6\12 8\12 2\12 0\12 0\12
CGI-Improvement 1\2 1\2 2\2 0\2 0\2 0\2
PGI-Improvement 9\12 7\12 8\12 2\12 2\12 0\12
Somatic Symptom Inventory
26-item Average score 2\10 2\10 7\10 3\10 0\10 0\10
28-item Average score 3\10 2\10 7\10 3\10 1\10 0\10
VAS Pain Severity
Overall pain 3\10 4\10 2\10 8\10 1\10 2\10
Headaches 1\10 0\10 5\10 5\10 1\10 0\10
Back pain 2\10 2\10 6\10 4\10 1\10 1\10
Shoulder pain 2\10 1\10 3\10 6\10 2\10 1\10
Daily activities 1\10 0\10 2\10 8\10 1\10 0\10
Pain while awake 2\10 2\10 5\10 5\10 1\10 1\10
QLDS Total score 1\4 2/4 1\4 2\4 0\4 1\4
Totals 84\202 70\202 110\202 69\202 25\202 11\202
1. Some of the eight trials included more than one dose arm. Therefore, an individual outcome could be assessed in as many as 12 comparisons with 
placebo.
Table 4: MMRM and LOCF_ANCOVA analysis of three focus outcomes from duloxetine clinical trials.
Study 1 Study 2 Study 3 Study 4 Study 5 Study 6 Study 7 Study 8
Dose 60 mg QD 60 mg QD 60 mg BID 60 mg BID 20 mg BID 40 mg BID 20 mg BID 40 mg BID 40 mg BID 60 mg BID 40 mg BID 60 mg BID
∆ p ∆ p ∆ p ∆ p ∆ p ∆ p ∆ p ∆ p ∆ p ∆ p ∆ p ∆ p
HAMD17Total Score
MMRM 4.9 < .001 2.2 .024 3.1 .009 0.9 .415 1.4 .143 1.5 .116 2.4 .034 3.6 .002 2.2 .001 3.3 < .001 1.4 .045 1.6 .014
LOCF 3.8 < .001 1.7 .048 2.1 .066 0.4 .681 1.2 .222 1.5 .138 2.4 .022 3.1 .003 2.2 .007 3.0 < .001 0.9 .253 1.5 .054
HAMD17 Maier Subscale
MMRM 2.8 < .001 1.6 .003 2.0 .005 0.7 .282 1.2 .037 1.4 .012 1.1 .068 1.7 .005 1.4 < .001 2.0 < .001 0.9 .022 1.2 .002
LOCF 2.3 < .001 1.4 .007 1.0 .030 0.6 .481 1.0 .058 1.3 .012 1.5 .028 1.8 .004 1.4 .001 1.9 < .001 0.7 .090 1.0 .014
VAS Overall Pain Severity
MMRM 5.9 .055 4.4 .135 NA NA 0.3 .931 1.2 .731 1.0 .771 7.4 .035 5.5 .085 6.3 .050 5.6 .044 1.3 .625
LOCF 6.9 .019 5.2 .037 NA NA 3.5 .573 3.5 .647 3.2 .710 7.1 .048 6.1 .063 5.6 .086 7.8 .014 5.5 .066
NA = not assessedBMC Psychiatry 2004, 4:26 http://www.biomedcentral.com/1471-244X/4/26
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total score was 2.4 from MMRM analyses compared with
2.0 from LOCF_ANCOVA. Thus, the advantage of duloxe-
tine over placebo, based on LOCF_ANCOVA results, was
approximately 83% as large as the advantage from
MMRM.
Similar results were obtained for the Maier subscale. Thus,
the advantage of duloxetine over placebo in mean change
from baseline to endpoint from MMRM was greater than
that from LOCF_ANCOVA in 9/12 comparisons (Table
4). The p-value from MMRM was lower than that from
LOCF_ANCOVA in 6/12 comparisons, while
LOCF_ANCOVA produced a lower p-value in 2 cases, and
p-values were identical in the remaining four cases. In 2/
12 comparisons MMRM yielded a significant difference
when LOCF_ANCOVA did not, while there was one
instance in which LOCF_ANCOVA yielded a significant
difference when MMRM did not. Averaged over all eight
studies, the advantage of duloxetine over placebo in mean
Maier subscale score was 1.5 from MMRM analyses com-
pared with 1.3 from LOCF_ANCOVA. Thus, the advantage
of duloxetine over placebo based on LOCF_ANCOVA
results was approximately 87% as large as the advantage
from MMRM.
For VAS overall pain severity, the advantage of duloxetine
over placebo from MMRM analyses was greater than the
corresponding advantage from LOCF_ANCOVA in 2/10
comparisons (Table 4). The p-value from MMRM was
lower than that from LOCF_ANCOVA in 2/10 compari-
sons, while in the remaining 8 comparisons the p-value
from LOCF_ANCOVA was lower than that from MMRM.
In 1 comparison MMRM yielded a significant difference
when LOCF_ANCOVA did not, while in 2 comparisons
LOCF_ANCOVA yielded a significant difference when
MMRM did not. Over all eight studies, the average advan-
tage of duloxetine over placebo in VAS overall pain sever-
ity was 3.9 from MMRM analyses compared with 5.4 from
LOCF_ANCOVA. Thus, the advantage of duloxetine based
on LOCF_ANCOVA results was approximately 138% as
large as the advantage from MMRM.
Case Studies
Mean changes in HAMD17 total score and VAS overall
pain severity from two studies (Studies 1 and 2) are used
to further illustrate MMRM and LOCF_ANCOVA (analysis
of variance with missing data imputed via last observation
carried forward) results. Results from these studies were
originally reported by Detke et al [10,11]. In both studies
the advantage of duloxetine over placebo in HAMD17 total
score tended to increase over time whereas duloxetine's
advantage in VAS overall pain was greatest at intermediate
visits (Tables 5 and 6).
In the case of the HAMD17 total score, advantages for
duloxetine over placebo at endpoint (Week 9) from
MMRM in Studies 1 and 2 were 4.86 (p < .001) and 2.17
(p = .024), respectively. The corresponding advantages
from LOCF_ANCOVA were 3.80 (p < .001) and 1.73 (p =
.048). Although the differences were significant for both
methods in both studies, MMRM yielded treatment con-
trasts that were approximately 25% greater than
LOCF_ANCOVA.
Table 5: MMRM and LOCF_ANCOVA analyses of HAMD17 total score in Studies 1 and 2.
STUDY 1 STUDY 2
MMRM
THERAPY Week N Mean 
change
Std.error p-value N Mean 
change
Std.error p-value
DULOX 1 121 -2.89 0.36 .435 123 -2.89 0.38 .601
PLACEBO 1 115 -2.50 0.37 136 -2.64 0.36
DULOX 2 112 -5.72 0.49 < .001 109 -5.54 0.48 .071
PLACEBO 2 110 -3.39 0.50 129 -4.43 0.45
DULOX 3 105 -7.37 0.53 < .001 108 -6.82 0.55 .287
PLACEBO 3 103 -4.58 0.54 122 -6.06 0.52
DULOX 5 100 -8.76 0.60 < .001 98 -8.58 0.66 .116
PLACEBO 5 101 -5.74 0.60 111 -7.20 0.62
DULOX 7 91 -9.93 0.64 < .001 89 -10.14 0.69 .008
PLACEBO 7 93 -5.82 0.65 97 -7.69 0.65
DULOX 9 84 -10.91 0.70 < .001 81 -10.46 0.71 .024
PLACEBO 9 89 -6.05 0.69 90 -8.29 0.67
LOCF_ANCOVA
DULOX LOCF_ANCOVA 121 -9.47 0.63 < .001 123 -8.75 0.71 .048
PLACEBO LOCF_ANCOVA 115 -5.67 0.66 136 -7.02 0.68BMC Psychiatry 2004, 4:26 http://www.biomedcentral.com/1471-244X/4/26
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For VAS overall pain, the advantage of duloxetine over
placebo at endpoint from MMRM in Studies 1 and 2 were
5.88 (p = .055) and 4.40 (p = .135), respectively. The cor-
responding advantages from LOCF_ANCOVA were 6.91
(p = .019) and 5.17 (p = .037). In both studies, the end-
point differences were significant from LOCF_ANCOVA,
but not from MMRM. The LOCF_ANCOVA treatment
contrasts were approximately 15% greater than those
from MMRM.
Standard errors from LOCF_ANCOVA were approxi-
mately 5% smaller than the Week 9 standard errors from
MMRM for both the HAMD17 total score and VAS overall
pain.
Discussion
In many areas of clinical research, the impact of missing
data can be profound [2,12-14]. Traditional approaches
to analyses of data from clinical trials with dropouts, such
as LOCF_ANCOVA, have focused on ease of implementa-
tion and interpretation. However, simple methods rely
upon assumptions that are often unrealistic. For example,
LOCF_ANCOVA assumes that patient dropout is com-
pletely random, i.e. it is unrelated to the outcome being
analyzed. Hence, in an analysis of efficacy data,
LOCF_ANCOVA assumes that patients do not drop out
due to lack of efficacy. The LOCF_ANCOVA approach also
assumes that, for those patients who drop out, their obser-
vations would not have changed had they stayed in the
trial. When these assumptions do not hold true, estimates
of treatment effects and associated standard errors may be
biased [2-4,6,7,15-17].
Considerable advances in statistical methodology, and in
our ability to implement these methods, have been made
in recent years. Methods such as MMRM, which require
less restrictive assumptions regarding missing data, may
now be easily implemented with standard software
[4,5,18,19].
No universally superior approach to analysis of longitudi-
nal data exists. However, a series of studies [6-9] demon-
strated empirically what may have been anticipated from
statistical theory – namely that the MMRM approach,
while providing no guarantee of immunity from bias due
to subject dropout, was a sensible analytic choice for
many clinical trial scenarios. MMRM has repeatedly been
shown to provide adequate control of Type I (false posi-
tive) and Type II (false negative) errors in a wide variety of
situations modeled after neuropsychiatric clinical trials.
In these head-to-head comparisons involving 456,000
data sets, the LOCF_ANCOVA approach did not perform
as well as MMRM. We therefore specified MMRM as the
primary analysis and LOCF_ANCOVA as a secondary
analysis in the Phase III clinical trials of duloxetine in the
treatment of MDD.
Similar results regarding control of Type I and Type II
error for LOCF_ANCOVA and mixed-effects model analy-
ses have been obtained independently [16,20-22]. Fur-
thermore, following an independent investigation of data
from two placebo- and active-comparator controlled
duloxetine trials, in which treatments were coded A, B, C,
etc.  to blind analysts to the treatment names, Molen-
berghs et al [4] concluded that MMRM analysis was a sen-
sible choice for those data.
Table 6: MMRM and LOCF_ANCOVA analyses of VAS overall pain severity in Studies 1 and 2.
STUDY 1 STUDY 2
MMRM
THERAPY Week N Mean 
change
Std.error p-value N Mean 
change
Std.error p-value
DULOX 1 120 -2.69 1.97 .181 121 -2.02 1.89 .157
PLACEBO 1 113 1.04 2.04 134 1.38 1.79
DULOX 2 113 -8.20 1.87 .003 108 -6.95 2.04 .003
PLACEBO 2 108 -0.42 1.93 127 0.91 1.90
DULOX 3 105 -10.46 1.95 .005 106 -9.81 1.90 < .001
PLACEBO 3 101 -2.56 2.01 119 -1.59 1.78
DULOX 5 99 -8.68 2.20 .028 95 -9.70 2.05 .011
PLACEBO 5 99 -1.85 2.24 108 -2.92 1.92
DULOX 7 91 -10.25 2.34 .016 87 -8.91 2.12 .254
PLACEBO 7 92 -2.26 2.38 94 -5.76 2.01
DULOX 9 83 -8.68 2.18 .055 80 -10.05 2.24 .135
PLACEBO 9 88 -2.80 2.20 88 -5.65 2.12
LOCF_ANCOVA
DULOX LOCF_ANCOVA 121 -8.31 2.09 .019 121 -10.39 2.05 .037
PLACEBO LOCF_ANCOVA 114 -1.40 2.18 134 -5.22 1.94BMC Psychiatry 2004, 4:26 http://www.biomedcentral.com/1471-244X/4/26
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The theoretical differences between MMRM and
LOCF_ANCOVA have been summarized [5,18], estab-
lished empirically [6-9], and proven mathematically [4].
However, we are unaware of any previous investigations
of how these differences manifest themselves in efficacy
assessments of a new medicinal product.
The VAS pain results highlight a limitation of endpoint
analyses of any type, namely that they provide only a
snapshot view of the response profile. From
LOCF_ANCOVA analysis, one can only conclude that
drug was superior to placebo at endpoint. However,
MMRM analysis reveals that drug had a significant effect
early in the trials, but that advantage was somewhat tran-
sitory as the placebo group tended to "catch up" over
time. In order to understand the response profile of a
drug, the entire longitudinal profile should be considered
[2]. From MMRM, the entire profile can be assessed from
the same analysis that provided the primary result (the
contrast at endpoint).
In the duloxetine database, results from MMRM and
LOCF_ANCOVA were in general agreement regarding
substantial evidence of efficacy and frequency of signifi-
cant differences. However, MMRM tended to be more sen-
sitive to drug-placebo differences for outcomes related to
overall depressive symptoms and core emotional symp-
toms of depression, with mean advantages over placebo
that were 10% to 20% greater than LOCF_ANCOVA.
However, MMRM did not universally increase duloxet-
ine's advantage over placebo in comparison to results
from LOCF_ANCOVA. For example, in somatic and pain-
ful physical symptom outcomes, results from
LOCF_ANCOVA showed mean advantages over placebo
that were approximately 40% greater than that from
MMRM.
Therefore, while the overall conclusions regarding the effi-
cacy of duloxetine were unaffected by the choice of
analytic method, this should not mask the important dif-
ferences between MMRM and LOCF_ANCOVA. The
advantages of MMRM and similar methods over
LOCF_ANCOVA have been conclusively demonstrated in
many studies and are evident in the duloxetine data.
Khan et al [23] compiled a database from FDA summaries
of efficacy for all antidepressants approved between 1985
and 2000. Less than half of the studies – which were ana-
lyzed using LOCF_ANCOVA as the primary analysis –
found significant advantages for drug over placebo. These
studies were generally anticipated to have at least 80%
power and, if the analysis worked as expected, the success
rate would be 80%. Therefore, LOCF_ANCOVA was less
sensitive to the drug effects than anticipated. In the
duloxetine database, MMRM yielded a 75% success rate
for the primary outcome measure (HAMD17 total score),
while LOCF_ANCOVA produced a 50% success rate, in
comparison to the expected rate of 80%. While many fac-
tors may reduce the success rate in Phase III clinical trials,
the use of a statistical method with known inflation of
Type II error (false negative results) is an obvious suspect.
An unduly high rate of false negative results could be espe-
cially problematic in early phases of drug development
where only one or two chances exist to make the correct
decision regarding the efficacy of a drug. It is noteworthy
that one of the instances when MMMRM yielded a signif-
icant difference on the primary outcome (HAMD17 total
score) when LOCF did not was in the Phase II study
(Study 3).
Also consider that across all therapeutic areas only about
50% of the molecules that enter Phase III testing receive
regulatory approval. Many factors may reduce the success
rate of Phase III development. However, the use in Phase
II of a statistical method with known inflation of Type I
error (false positive results) is an obvious suspect. Thus,
the unexpectedly low success rate in Phase III is consistent
with the conclusion that LOCF_ANCOVA inflates Type I
error (as a result of an unduly high rate of false positive
results in Phase II).
Hence, results from the duloxetine NDA are consistent
with research suggesting a move away from
LOCF_ANCOVA and other simple analytic techniques to
methods such as MMRM that are more robust to the
biases from missing data.
Conclusion
Important differences exist between MMRM and
LOCF_ANCOVA. Research has clearly demonstrated the
advantages of MMRM over LOCF_ANCOVA. However,
interpretations regarding the efficacy of duloxetine in
MDD were unaffected by the choice of analytical
technique.
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